Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Aktis Oncology, Inc.
Mayo Clinic
University of Washington
Northwestern University
Centre Hospitalier Universitaire, Amiens